The effect of adenovirus-mediated interleukin-2 (IL-2) gene on rat basal nociceptive response and chronic neuropathic pain was explored. The paw withdrawal latency induced by radiant heat was used to evaluate the antinociceptive effect of adenovirus type 5 (Ad5) and Ad5-IL-2. The results showed that intrathecal delivery of Ad5-IL-2 exhibited obvious antinociceptive effects on basal nociceptive response and chronic neuropathic pain, which were maintained for 3 and 4 weeks, respectively. This suggested that the antinociceptive effect of Ad5-IL-2 on chronic neuropathic pain was greater than its effect on basal nociceptive response. Human IL-2 mRNA was detected by in situ hybridization in the spinal pia mater and parenchyma of the lumbar, sacral, thoracic and cervical regions, and gray matter had higher level of IL-2 expression than white matter. These data demonstrated that the IL-2 gene was transfected into spinal cord regions relevant to pain modulation. The expressed IL-2 protein profile in spinal cord detected by enzyme-linked immunosorbent assay coincided almost exactly with its antinociceptive effect. This supported the hypothesis that the therapeutic effect of IL-2 gene was related to IL-2 protein expression. The study indicates that intrathecal delivery of adenovirusmediated IL-2 gene has a relatively long antinociceptive effect.
Introduction
Interleukin-2 (IL-2) is not only an important immunoregulatory molecule, but also an important neuroregulatory molecule in the central nervous system (CNS).
1,2 IL-2 and the IL-2 receptor are widely distributed in rat CNS, mainly localized in hippocampus, hypothalamus, cerebellum, neostriatum, 3 and dorsal root ganglion (DRG) neurons. 4 Inhibitory functions of IL-2 have also been shown in the CNS by decreasing activity in the anterior hypothalamus, 5 suppressing long-term potentiation in the hippocampus and inducing depolarization in hippocampal neurons. 6 We have previously reported that IL-2 has an antinociceptive (analgesic) effect in both central and peripheral nervous systems, 7, 8 inhibits nociceptive responses of the spinal dorsal horn neurons, 9 and this antinociceptive effect can be mediated by IL-2 binding to opioid receptors. 8, 10 The antinociceptive domain is located at the Phe 44 , Tyr 45 , Tyr 107 , and Phe 117 residues of human IL-2.
11,12 Microinjection of IL-2 in intracerebroventricle (i.c.v.), hippocampus or locus coeruleus could increase the pain threshold. [12] [13] [14] The antinociceptive effect was related to the increase of Leu-enkephalin in paraventricular hypothalamic nucleus and locus coeruleus, 15 the increase of substance P (SP) in periaqueductal gray, the decrease of SP in the spinal cord and the reduction of Fos protein in superficial dorsal horn. 13, 14 However, as we have discovered, IL-2 has very short half-life in vivo. [16] [17] [18] Systemic administration of IL-2 at pharmacological doses produces short-lived high concentrations of IL-2 in the vasculature and suboptimal levels in the nervous system. It is impractical to apply IL-2 for analgesia in clinic. To achieve curative effect, IL-2 must be continuously administered, resulting in high cost and inconvenience to patients. Therefore, we observed the effect of plasmid-mediated IL-2 gene therapy on chronic neuropathic and inflammatory pain. 19, 20 The results showed that the IL-2 gene has a marked antinociceptive effect, and the antinociceptive effect by intrathecal delivery is superior to subcutaneous delivery. In order to put the antinociceptive effect of IL-2 into practical use, in this study we tried to adopt an adenovirus-mediated gene therapy system to evaluate the effect of intrathecal delivery of IL-2 gene on rat basal nociceptive response and chronic neuropathic pain.
Results

Interleukin-2 gene expression in Ad5-IL-2-infected cells
To test human IL-2 gene expression of recombinant Ad5-IL-2, we detected IL-2 mRNA in COS-7 cells 2 days after Ad5 or Ad5-IL-2 infection. The result showed that IL-2 mRNA could be detected by RT-PCR in Ad5-IL-2-infected cells, but not in Ad5-infected ones (Figure 1 ).
To validate the protein expression efficiency of Ad5-IL-2, the bioactivity of IL-2 in COS-7 cells culture supernatant was assayed 2 days after adenovirus infection. The result showed that the bioactivity of IL-2 could be detected, which reached 700760 IU/1 Â 10 6 cells/48 h after Ad5-IL-2 infection (Po0.01 versus Ad5 infection, n¼4), whereas there was no IL-2 production in the culture supernatant after Ad5 infection. It verified that the recombinant Ad5-IL-2 had high expression efficiency when transfected into mammalian cells.
Effect of intrathecal Ad5-IL-2 delivery on basal nociceptive response
To investigate the effect of Ad5-IL-2 on basal nociceptive response, rats were intrathecally delivered with vehicle, Ad5, or Ad5-IL-2. The paw withdrawal latency (PWL) induced by radiant heat was measured weekly for 5 weeks. The results showed that the PWL was not affected by intrathecal delivery of vehicle or Ad5 (P40.05, compared with the PWL before intrathecal delivery). However, intrathecal delivery of Ad5-IL-2 showed antinociceptive effects on basal nociceptive response. The antinociceptive effect of Ad5-IL-2 reached peak 1 week after intrathecal delivery and could be maintained for 3 weeks (Po0.05 versus Ad5 delivery) (Figure 2 ).
Effect of intrathecal Ad5-IL-2 delivery on chronic neuropathic pain
To explore the effect of Ad5-IL-2 on chronic neuropathic pain, rats were intrathecally delivered with vehicle, Ad5, or Ad5-IL-2 2 weeks after chronic constriction injury (CCI) of the sciatic nerve. The PWL was measured weekly for 6 weeks after intrathecal injection. The results showed that the intrathecal delivery of Ad5-IL-2 had obvious antinociceptive effect on chronic neuropathic pain, which reached peak 1 week after intrathecal injection. The antinociceptive effect of Ad5-IL-2 on chronic neuropathic pain could be maintained up to 4 weeks (Po0.05 versus Ad5 delivery), and lasted longer than the effect on basal nociceptive response. The PWL was not affected by intrathecal delivery of vehicle or Ad5 (P40.05, compared with the PWL before intrathecal delivery) (Figure 3 ).
Interleukin-2 mRNA expression in spinal cord after intrathecal Ad5-IL-2 delivery
To confirm the expression of exogenous human IL-2 gene after intrathecal delivery of Ad5-IL-2 and also to Figure 2 Effect of intrathecal Ad5-IL-2 delivery on basal nociceptive response. After rats were intrathecally injected of vehicle (5% sucrose in PBS), Ad5 (5 Â 10 7 PFU), and Ad5-IL-2 (5 Â 10 7 PFU) in a total volume of 10 ml, respectively, the PWL was measured weekly for 5 weeks after injection. '0' is the time point before intrathecal delivery. Significance is defined as **Po0.01, *Po0.05 versus Ad5 delivery (n¼14-16). Figure 3 Effect of intrathecal Ad5-IL-2 delivery on chronic neuropathic pain. After CCI for 2 weeks, rats were intrathecally injected of vehicle (5% sucrose in PBS), Ad5 (5 Â 10 7 PFU), and Ad5-IL-2 (5 Â 10 7 PFU) in a total volume of 10 ml, respectively. The PWL was measured weekly for 6 weeks after injection. '0' is the time point before intrathecal delivery. Significance is defined as **Po0.01, *Po0.05 versus Ad5 delivery (n¼16-18).
Interleukin-2 gene therapy of nociception MZ Yao et al elucidate the molecular basis of its antinociceptive effect, we detected human IL-2 mRNA in the spinal cord of CCI rats by in situ hybridization. The results showed that 1 week after intrathecal Ad5-IL-2 injection, when its therapeutic effect reached the peak, IL-2 mRNA could be detected in the spinal pia mater and parenchyma of the lumbar (Figure 4d-f) , sacral, thoracic and cervical regions. The strongest expression in all regions was in the lumbar, followed by the sacral, thoracic and cervical regions (data not shown). Moreover, the gray matter of spinal cord had a much higher level of expression than the white matter. The data indicated that the IL-2 gene could be transfected into spinal cord regions relevant to pain modulation. However, the signal of human IL-2 mRNA was not detected after Ad5 injection (Figure 4a -c).
Interleukin-2 protein expression level in spinal cord after intrathecal Ad5-IL-2 delivery
To further verify whether the therapeutic effect of Ad5-IL-2 is related to different IL-2 protein expression levels, enzyme-linked immunosorbent assay (ELISA) was employed to quantify the IL-2 level in the lumbar region of the spinal cord of CCI rats after intrathecal injection. The results showed that IL-2 protein was detected in spinal cord 1-6 weeks after intrathecal Ad5-IL-2 injection Figure 5 ). These results suggested that the therapeutic effect of Ad5-IL-2 was related to IL-2 protein expression levels in the spinal cord.
Discussion
We have previously reported that IL-2 has an antinociceptive (analgesic) effect in both central and peripheral nervous systems. 7, 8 However, the half-life (t 1/2 ) of IL-2 is very short in serum, the first phase t 1/2 approximately 12.9 min during which most of the exogenous IL-2 was cleared from the serum; and the second phase about 85 min. 18 Thus, it was impractical to apply IL-2 for analgesia in clinic. In order to put the antinociceptive effect of IL-2 into practical use, plasmid-mediated IL-2 gene therapy has been carried out using rat models of chronic neuropathic pain and inflammatory pain. 19, 20 The results showed that intrathecal or plantar subcutaneous delivery of pcDNA3-IL-2 produced a marked antinociceptive effect, which was maintained for 6 days. To further explore a strategy for long-term expression of IL-2, in this study we chose an adenovirus-mediated gene therapy system to evaluate the antinociceptive effect of IL-2 gene on rat basal nociceptive response and chronic neuropathic pain.
A limitation of current gene therapy aimed at nervous system disorders concerns the distribution of vectors in neural tissue. Considering that the adenovirus vector has advantages of infection of both dividing and nondividing cells, reproducibility and safety, we chose the adenovirus-mediated gene therapy system in this study. The route of gene delivery is also a problem worthy of consideration. The spinal dorsal horn contains the first set of synaptic contacts that process and relay incoming nociceptive (pain) stimulation. Information related to noxious thermal, mechanical, and chemical stimuli is transmitted from the skin and other peripheral sites to the CNS by myelinated Ad and unmyelinated C nociceptors. Both types of neurons synapse in the dorsal horn of the spinal cord onto various secondorder neurons that either carry information to thalamus and other brain centers or synapse on other spinal neurons. Injecting drugs into the spinal fluid is a useful method in research on analgesia under unanesthetized, unsedated and unrestrained conditions. The intrathecal delivery of recombinant adenovirus encoding b-endorphin has been reported in an inflammation model of persistent pain. The results showed that administration of the vector into cerebrospinal fluid (CSF) could attenuate inflammatory hyperalgesia. 21 In previous studies, we have observed that the IL-2 gene has superior antinociceptive effect when delivered intrathecally. 20 Therefore, we adopted the route of intrathecal gene delivery in this study.
The postoperative behavior of rats with CCI indicated that hyperalgesia, allodynia and possibly, spontaneous pain (or dysesthesia) were produced. Hyperalgesic responses to noxious radiant heat were evident on the second postoperative day and lasted for over 2 months. Hyperalgesic responses to chemogenic pain were also present. The presence of allodynia was inferred from the nocifensive responses. 22 As concerning the method to measure cutaneous hyperalgesia, the mechanical method for allodynia uses a nonautomated detection of the behavioral end point, which requires substantial observer interaction. Paradoxically, the method using noxious radiant heat as a thermal stimulus can let the animal move freely in the cage and have a greater bioassay sensitivity compared to the mechanical method. 23 In view of the above reasons, we chose the nociceptive responses to noxious radiant heat as an index to test the effect of Ad5-IL-2 on rat nociceptive model. We observed that intrathecal delivery of Ad5-IL-2 had an antinociceptive effect on basal nociceptive response. This indicated that the thermal pain threshold of normal animals was reset to a relative higher range after intrathecal injection with Ad5-IL-2. The results coincided with our previous animal experiments, which showed that IL-2 injection (i.c.v.) could increase the basal pain threshold. 8, 9 In addition, we observed that intrathecal delivery of Ad5- , and Ad5-IL-2 (5 Â 10 7 PFU) in a total volume of 10 ml respectively, the level of IL-2 in rat spinal cord of CCI rats was analyzed by ELISA. '0' is the time point before intrathecal delivery. Significance is defined as **Po0.01, versus Ad5 delivery (n¼4-6).
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To explore the molecular and anatomical basis of the antinociceptive effect produced by Ad5-IL-2, we detected IL-2 mRNA expression in spinal cord by in situ hybridization. The results showed that after Ad5-IL-2 intrathecal injection, IL-2 mRNA was detected not only in regions of the spinal pia mater but also in parenchyma; and the gray matter of spinal cord had a much greater level of expression than the white matter. It indicated that IL-2 gene was transfected into spinal cord regions relevant to pain modulation. Similar results were reported by other researchers, which revealed that the intrathecal injection of AdCMVb-gal increased lacZ activity in spinal cord parenchyma and pia mater; however, the pia mater displayed a higher level of expression. 24 ELISA assay showed that the expression level of IL-2 protein in spinal cord coincided with the antinociceptive effect of Ad5-IL-2. Our previous study suggested when pcDNA3-mediated IL-2 gene was intrathecally delivered, the IL-2 expressed in the pia mater could be secreted into the spinal cord parenchyma. 19 Therefore, it is highly likely that the majority of the IL-2 in parenchyma is coming from the pia mater. In this study, there is no strong evidence that the expression of IL-2 in the relevant parenchyma regions (other than the IL-2 released from the pia mater) contributes significantly to the observed antinociceptive effect.
The mechanism underlying IL-2-induced antinociception is unclear. Previous studies have shown that IL-2 and morphine could exert various similar effects by decreasing intracellular cAMP concentration, modulating neuroendocrine activity, suppressing afferent sensory transmission, and acting as Ca 2+ channel blockers. 25, 26 Naloxone, an opioid receptor antagonist, could decrease IL-2-induced antinociceptive effect, 8 indicating the involvement of the opioid receptor in this process. However, there was also a report that recombinant IL-2 (rIL-2) had marked antinociception on morphine-tolerant rats and rIL-2 antinociception was only partially blocked by naloxone in normal rats. 10 This suggested the possibility that some other receptors were involved in IL-2-induced antinociception. The central neurons in the dorsal horn of spinal cord may express many molecules related to pain modulation, [27] [28] [29] which include m-, d-, and k-opioid receptors. We found that IL-2 gene was transfected into these opioid-receptor-located regions. In our previous studies, we observed the IL-2-gene-induced antinociceptive effect could be reversed by naloxone. 19 Therefore, IL-2-gene-induced antinociception might also be attributed to an interaction between IL-2 and the opioid system. This is the first study of intrathecal delivery of Ad5-IL-2 for antinociception in order to prolong the therapeutic time of IL-2. The results showed that intrathecal delivery of Ad5-IL-2 had an obvious antinociceptive effect on chronic neuropathic pain, and the antinociceptive effect produced by Ad5-IL-2 was much longer than plasmidmediated IL-2 gene.
Materials and methods
Adenovirus vector construction and recombination
The cDNA of human IL-2 gene was obtained using PCR from the cDNA pool of mononuclear cells from human peripheral blood. 30 A 462 bp XhoI-EcoRI fragment of the whole-length IL-2 cDNA was cloned into a shuttle plasmid pCA13 (Microbix, Toronto, Canada), which contained human cytomegalovirus (CMV) immediateearly promoter/enhancer, a polycloning linker containing unique restriction site, and SV40 polyadenylation signals, and produced pCA13-IL-2. Adenoviral packaging vector pBHG10 (Microbix, Toronto, Canada) was cotransfected into human embryonic kidney (HEK) 293 cells with pCA13 or pCA13-IL-2, respectively, mediated by Lipofectaminet (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer's protocol. Through homologous recombination, E1A-deleted virus Ad5 or Ad5-IL-2 was generated. The replication-deficient viruses were plaque-purified twice, propagated, concentrated and purified by double cesium chloride (CsCl) gradient centrifugation. The titers of Ad5 or Ad5-IL-2 were determined by plaque assay using HEK 293 cells. Virus was diluted by 5% sucrose in phosphate-buffered saline (PBS) before injection.
RT-PCR for detection of interleukin-2 mRNA expression in vitro
COS-7 cells were grown in DMEM supplemented with 10% fetal bovine serum without antibiotics. COS-7 cells in six-well culture plates at about 80% confluence were infected with Ad5 or Ad5-IL-2 at a multiplicity of infection (MOI) of 20. The infection was carried out for 3 h at 371C; then the medium was removed and replaced with fresh medium. After 2 days of incubation, the total cellular RNA was isolated using TRIzol reagent (Life Technologies, Grand Island, NY, USA) according to the manufacturer's protocol. The purity and quantity of the isolated RNA were determined by an ultraviolet spectrophotometer (OD260/OD280), after which 2 mg of total RNA was reversely transcribed into the complementary DNA strand (cDNA). The RNA was incubated at 371C for 60 min with a mixture of 200 units of M-MuLV reverse transcriptase (Promega, Madison, WI, USA), 1 Â RT buffer, 1.25 Â 10 À5 mM each of dNTP, 25 units of ribonuclease inhibitor, and 0.2 mg of DNA random hexamer primer in a volume of 25 ml. Following this, the reaction mixture was incubated at 951C for 5 min to denature the RNA-cDNA hybrid and to inactivate the reverse transcriptase. A volume of 1 ml of RT product was mixed with 2.5 units of Pfu DNA polymerase, 20 pmol each of sense and antisense primers in a buffer containing 10 mM of Tris-HCl (pH 8.3), 50 mM of KCl, 2.5 mM of MgCl 2 , and 0.25 mM of each dNTP in a volume of 50 ml. The primers used in this experiment were 5 0 -ATGTA CAGGATGCAACTCCT-3 0 (sense) and 5 0 -TCAAGT CAGTGTTGAGATGA-3 0 (antisense) for human IL-2, and 5 0 -CCAGCCATGTACGTTGCTATCCAG-3 0 (sense), 5 0 -GGAACCGCTCATTGCCAATGGTGA-3 0 (antisense) for b-actin whose expression served as internal control. The amplified DNA fragments were expected to be 462 bp (IL-2) and 378 bp (b-actin). The PCR cycles consisted of preincubation at 941C for 7 min, denaturation at 941C for 1 min, annnealing at 501C for 1 min, and
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Bioactivity assay of interleukin-2 protein expression in vitro
COS-7 cells were infected with Ad5 or Ad5-IL-2 as described above. Cell culture supernatant was collected after 2 days of incubation. The bioactivity of IL-2 in culture supernatant was assayed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, which utilizes IL-2-dependent murine cell line CTLL-2. 31 The bioactivity was quantified with IL-2 from Boehringer Mannheim as a standard.
Experimental animals
Male Sprague-Dawley rats (240-260 g) were provided by the Shanghai Experimental Animal Center of Chinese Academy of Sciences, and were housed one per cage at a room temperature of 221C, with food and water ad libitum and a 12 h light : dark cycle.
In animal experiments, all efforts were made to minimize both the suffering and the number of animals used. All animal experiments were approved by the Administrative Committee of Experimental Animal Care and Use of Shanghai, and conformed to the National Institute of Health (NIH) guidelines on the ethical use of animals.
Chronic constriction injury (CCI)
Rats were anesthetized with sodium pentobarbital (40 mg/kg, intraperitoneal, i.p.; supplemented as necessary). The common sciatic nerve was exposed at the midthigh level. Four ligatures of 4-O chromic gut were tied loosely around the nerve with about 1 mm spacing between knots. At the time of tying, the ligatures just barely reduce the nerve diameter. Over time, the ligatures evoke intraneural edema, resulting in constriction. 22 The incision was closed in layers. Upon recovery from anesthesia, the animals were housed postoperatively in individual clear plastic cages with solid floors covered with 3-6 cm of soft bedding (sawdust), with free access to food and water. The model of chronic neuropathic pain was evaluated before lumbar subarachnoid catheterization, and the rats with the paw withdrawal latency (PWL) exceeding 6.5 s were eliminated from this study.
Lumbar subarachnoid catheterization
The rats without operation or with CCI for 10 days were anesthetized with sodium pentobarbital (40 mg/kg, i.p.). A PE-10 catheter (Becton Dickinson, Sparks, MD, USA) was inserted into the lumbar subarachnoid space between lumbar vertebrae 5 (L5) and 6 (L6) space with 'catheter-through-a-needle' technique. 32 The catheter was chronically implanted. The external portion of the chronic indwelling catheter was protected according to Milligan's method. 33 Upon recovery from anesthesia, animals were returned to their home cages. A minimum of 4 days was allowed for recovery before intrathecal injection.
Measurement of pain threshold
The rats without operation or with CCI for 2 weeks were respectively injected vehicle (5% sucrose in PBS), 5 Â 10 7 PFU of Ad5, or 5 Â 10 7 PFU of Ad5-IL-2 intrathecally, n¼14-18. The total volume of injection was 10 ml. The PWL was measured weekly after injection.
To test pain threshold, paw withdrawal reflex was induced by radiant heat. Rats were placed under an inverted clear plexiglass cage (23 Â 18 Â 13 cm 3 ) on a piece of 3 mm thick glass plate. After acclimation, the radiant heat source was positioned under the glass floor directly beneath the hindpaw. The radiant heat source consisted of a high-intensity projection lamp bulb (8 V, 50 W) located 40 mm below the glass floor and projecting through a 5 mm Â 10 mm aperture in the top of a movable case. The PWL to radiant heat was measured. 23 A digital timer automatically read the duration between the start of stimuli and the paw withdrawal. The PWL was measured to the nearest 0.1 s. A cutoff time of 15 s of irradiation was used to avoid any tissue damage in this study.
In situ hybridization for detection of interleukin-2 mRNA expression in spinal cord CCI rats were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) 1 week after intrathecal Ad5 or Ad5-IL-2 delivery and perfused transcardially with 20 ml of saline followed by 400 ml of 4% paraformaldehyde in 0.1 M PBS (pH 7.4). The spinal cords were dissected out and postfixed for 12-24 h in the perfusion fixative before being transferred to 30% sucrose in 0.1 M PBS (pH 7.4) for 1-3 days. The spinal cords were sectioned transversely at a thickness of 30 mm on a cryostat at À181C and stored at À701C until hybridized. IL-2 mRNA was detected using human IL-2 in situ hybridization detection kit (Boster, Wuhan, China). The digoxin (DIG)-labeled in oligonucleotide probes used in the experiment were 5 0 AGATGTTTCAGTTCTGTGGCC-TTCTTGGGCATGTA3 0 , 5 0 GATATTGCTGATTAAGTCC-CTGGGTCTTAAGTGAA3 0 , and 5 0 CATCTGTTCAGAA-ATTCTACAATGGTTGTCGTCTC3 0 . Following the manufacturer's protocol, the sections were treated with 0.5% H 2 O 2 in methanol for 30 min at room temperature (RT), and digested with pepsin in 3% citric acid at 371C for 1 min. Then the sections were prehybridized with hybridization solution without probe at 401C for 2 h followed by being hybridized with hybridization solution in a humid chamber at 421C for 12 h. Next, the sections were washed in 2 Â SSC (300 mM sodium chloride, 30 mM sodium citrate, pH 7.2) twice for 5 min, 0.5 Â SSC for 15 min, and 0.2 Â SSC for 15 min and blocked with 0.5% bovine serum albumin (BSA) blocking solution for 30 min at 371C followed by reaction with biotinylated mouse anti-DIG antibody for 60 min at 371C. After that, the sections were reacted with streptavidinbiotin-peroxidase complex (SABC) for 20 min at 371C, then with biotinylated peroxidase for 20 min at 371C. Finally, the reacted sections were mounted onto Poly-L-Lysine (MW 3 Â 10 6 ) coated slides. The slides were reacted with diaminobenzidine (DAB) for 20 min, dehydrated through a graded series of ethanols, cleared in xylene, and coverslipped.
ELISA for IL-2 level in spinal cord tissue
CCI rats were anesthetized with ether after intrathecal injection for 1-6 weeks, and killed by decapitation, and the lumbar 4, 5, and 6 (L4-6) regions of spinal cord were Interleukin-2 gene therapy of nociception MZ Yao et al immediately dissected and the pia mater was stripped. The freshly dissected tissues of spinal cord were homogenized at 41C in lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.02% sodium azide, 100 mg/ml phenylmethylsulfonyl fluoride (PMSF), 1 mg/ml aprotinin, and 1% Nonidet P-40 (NP-40)). The homogenates were centrifuged at 12 000 g for 2 min, and the supernatants were collected, divided into aliquots and stored at À201C.
The IL-2 of tissue crude extracts was analyzed by ELISA kit (BioSource, Camarillo, CA, USA). Plates were coated with 100 ml/well mouse anti-human IL-2 monoclonal antibody at 1.0 mg/ml and incubated for 18 h at 41C, then were blocked by adding 300 ml of blocking solution to each well and incubated for 2 h at RT. Standards and tissue crude extracts were diluted with RPMI containing 10% fetal calf serum, and added at 100 ml/well followed immediately by addition of 50 ml/well of biotinylated mouse anti-human IL-2 antibody at 0.4 mg/ml. The plates were then incubated for 2 h at RT with continual shaking. After washes, 100 ml/well of streptavidin-HRP working solution was added and incubated for 30 min at RT. At last, 100 ml/well of the freshly prepared chromogen tetramethyl benzidine (TMB) was added and incubated for 30 min at RT with continual shaking in the dark followed by addition of 50 ml/well of stop solution. The optical density of the plates was measured at 450 nm (reference filter 650 nm).
Statistical analysis
Data were analyzed using the one-way analysis of variance (ANOVA). The post hoc student Newman Keuls test was also used for further analysis. Statistical significance was taken at Po0.05. Values are presented as mean7s.e.m.
